Arcutis Presents New Phase 2 Long-Term Data Showing Sustained Efficacy and Clearance for a Median of…
During the open label trial, 57.1% of roflumilast-treated participants achieved Investigator Global Assessment (IGA) of clear or almost clear at any time in study; the median duration of clear or almost clear was 10 months (40.1…